Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.

ABSTRACT:

Background

Rituximab and trastuzumab were the first therapeutic monoclonal antibodies (mAbs) approved in oncology. Both antibodies are delivered by the intravenous (IV) route, but recently subcutaneous (SC) formulations have been developed. Subcutaneous administration of mAbs can offer substantial patient and resource benefits compared with IV, but SC administration of some mAbs can be limited by drug volume. Recombinant human hyaluronidase (rHuPH20) temporarily degrades hyaluronan, allowing SC delivery of drug volumes that might not otherwise be feasible.

Methods

Clinical trials assessing coformulation of rituximab or trastuzumab with rHuPH20 for SC administration were reviewed.

Results

Phase I trials of rituximab SC maintenance therapy in patients with follicular ly

SUBMITTER: Shpilberg O 

PROVIDER: S-EPMC3776971 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature